Price-Driven Insight from (EYPT) for Rule-Based Strategy
This article provides a price-driven analysis for Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), indicating a near-term neutral sentiment amidst mid and long-term strength. It outlines various AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report also highlights a significant risk-reward short setup for the stock.
Guggenheim reiterates Buy on EyePoint stock, cites trial progress
Guggenheim has reiterated a Buy rating on EyePoint Inc. (NASDAQ:EYPT) with a $68.00 price target, citing promising progress in the company's clinical trials for wet age-related macular degeneration and diabetic macular edema. Enrollment is complete for the LUGANO and LUCIA trials, with topline data expected to begin in mid-2026, supporting a new drug application filing. Despite recent financial setbacks in Q1 2026, the company maintains a strong cash position and remains a top pick for Guggenheim.
EyePoint Pharmaceuticals outlines long-term retina strategy as a specialty biotech
EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing sustained drug delivery technologies for serious retinal diseases. The company aims to address the burden of frequent treatments for conditions like age-related macular degeneration by providing long-acting intravitreal therapies. EyePoint's business model centers on specialty ophthalmology, involving significant investment in R&D and potential collaborations with larger firms.
Form 4 Eyepoint Pharmaceuticals Inc For: 2 July By Investing.com
This article reports on a Form 4 filing for Eyepoint Pharmaceuticals Inc. for transactions that occurred on July 2nd. It is a brief announcement from Investing.com and does not contain further details within the main body. The article is surrounded by various financial market data, news headlines, and advertising.
EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock
EyePoint, Inc.'s Chief Medical Officer, Ramiro Ribeiro, recently sold 4,875 shares of company stock, totaling approximately $73,166, after exercising stock options. Following these transactions, Ribeiro holds no direct shares but retains 153,564 stock options. The company is reportedly burning through cash and is not expected to be profitable this year, with its stock trading below the sale price.
EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock By Investing.com
EyePoint's Chief Medical Officer, Ramiro Ribeiro, sold $73,166 worth of company stock after exercising options. These transactions, occurring on June 30, 2026, leave Ribeiro with no direct shares but 153,564 stock options. Despite the sale, the stock currently trades below the sale price, and the company is noted by InvestingPro as being overvalued and burning through cash.
Did Broad Russell Growth Index Additions Just Reframe EyePoint’s (EYPT) Small-Cap Biotech Profile?
EyePoint Pharmaceuticals, Inc. (EYPT) was recently added to several Russell growth indices, including the Russell 3000 Growth and 2000 Growth. This inclusion could boost the company's visibility among institutional investors and enhance liquidity, but it doesn't alter the core investment narrative which is heavily reliant on the successful development and commercialization of its drug DURAVYU. The company continues to face high losses and minimal revenue, making the Phase 3 DURAVYU data a critical near-term catalyst.
Did Broad Russell Growth Index Additions Just Reframe EyePoint’s (EYPT) Small-Cap Biotech Profile?
EyePoint Pharmaceuticals (EYPT) has been added to several Broad Russell Growth Indices, potentially increasing its visibility and liquidity with institutional investors. However, this inclusion does not alter the company's core investment narrative, which relies heavily on the success of its late-stage DURAVYU trials for wet-AMD and addressing ongoing heavy losses. Investors should focus on the upcoming Phase 3 DURAVYU data and the company's cash runway, as these remain critical factors for its future trajectory.
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark
EyePoint, Inc. (NasdaqGM: EYPT), a clinical-stage biopharmaceutical company focusing on treatments for serious retinal diseases, has been added to the Russell 2500 Growth Benchmark. The company's lead product candidate, DURAVYU, is currently in Phase III pivotal trials for wet age-related macular degeneration and diabetic macular edema. EyePoint Inc. has received a 'Buy' consensus rating from analysts with an average target price significantly above its last closing price.
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark
EyePoint, Inc. (NasdaqGM: EYPT) has been added to the Russell 2000 Growth Benchmark. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently undergoing Phase III trials for wet age-related macular degeneration and diabetic macular edema. Analysts have a consensus "BUY" rating for EYPT with an average target price of $37.00.
EYPT Forecast — Price Target — Prediction for 2027
This article provides an overview of EyePoint, Inc. (EYPT) stock performance and analyst forecasts. It includes the current stock price, historical highs and lows, market capitalization, volatility, and details on recent earnings and revenue. Analysts have provided target prices ranging from $20.00 to $68.00, with a consensus around $37.00.
Mizuho reiterates EyePoint stock rating on competitor timeline shift
Mizuho has reiterated an Outperform rating and $36.00 price target for EyePoint Inc. following news that a competitor, Ocular Therapeutix, has delayed its NDA submission timelines for a rival product. This development is seen as positive for EyePoint, which expects top-line results for its Duravyu Phase 3 program in August. Despite recent disappointing financial results for EyePoint, analysts maintain confidence in the company's clinical pipeline and future prospects.
Form 8K Eyepoint Pharmaceuticals Inc For: 22 June By Investing.com
This article from Investing.com announces Eyepoint Pharmaceuticals Inc.'s Form 8K filing for June 22. The publication provides general financial market data, including various indices, stock performances, and commodity prices, alongside this specific company update. It also features top news headlines and market movers, indicating a comprehensive financial news platform.
Form 8K Eyepoint Pharmaceuticals Inc For: 22 June By Investing.com
This article from Investing.com reports on an 8K filing by Eyepoint Pharmaceuticals Inc. The brief entry indicates that the filing pertains to June 22nd. No further details about the content of the 8K filing are provided in this specific news item.
EyePoint stockholders approve incentive plan amendment and elect directors
EyePoint, Inc. stockholders approved an amendment to the company's 2023 Long-Term Incentive Plan, increasing authorized shares by 4.9 million, and elected directors at their annual meeting. Key resolutions also included the approval of executive compensation and the ratification of Deloitte & Touche LLP as the independent accounting firm for 2026. This follows recent financial results from EyePoint Pharmaceuticals that missed expectations, although their clinical trials for DURAVYU are progressing as planned, leading Guggenheim to reiterate a "Buy" rating.
EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of EyePoint Pharmaceuticals Inc (EYPT), focusing on its price momentum, support and resistance levels, and key technical indicators. The stock currently has a price momentum score of 8.91 and is trading within a range suitable for swing trading. Technical indicators show a mixed signal with 2 buy, 2 neutral, and 1 sell, while moving averages suggest a stronger buy signal with 4 buys and 2 sells.
EyePoint Pharmaceuticals Inc (EYPT) Valuation: PE, PB & Fair Value Analysis
EyePoint Pharmaceuticals Inc (EYPT) currently holds a valuation score of 6.48, placing it 149th out of 157 in the Pharmaceuticals industry. Its P/E ratio stands at -3.87, representing a significant variance from its recent highs and lows. The company has not yet disclosed relevant data for its P/B, P/S, and P/CF ratios.
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence
EyePoint Pharmaceuticals Inc (EYPT) currently holds an institutional shareholding score of 10.00, placing it first among 157 companies in the Pharmaceuticals industry. The institutional shareholding proportion is 105.59%, which is a 16.25% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.14% of outstanding shares.
EyePoint Pharmaceuticals Inc (EYPT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for EyePoint Pharmaceuticals Inc (EYPT), detailing its business segments and regional contributions. As of April 6, the company's Q4 FY2022 revenue shows YUTIQ as a key product segment and the United States as the dominant regional contributor, with smaller revenue streams from China and the United Kingdom.
EyePoint Pharmaceuticals Inc (EYPT) Financial Health: Profitability & Balance Sheet Analysis
EyePoint Pharmaceuticals Inc (EYPT) currently holds a financial score of 5.96, ranking 149 out of 157 in the Pharmaceuticals industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue decreased by 97.15% year-over-year to $696.00K, alongside an 87.70% year-over-year decrease in net profit. Key financial data points for quality of earnings, operational efficiency, growth potential, and shareholder returns have not been fully disclosed by the company.
EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of EyePoint Pharmaceuticals Inc (EYPT) focusing on its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years. The article also lists multiple stock merger events that occurred on December 8, 2020, with a 10→1 ratio.
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for EyePoint Pharmaceuticals Inc (EYPT), highlighting its current earnings forecast score of 8.67, which ranks 13th in the Pharmaceuticals industry. Analysts have set an average price target of $33.00, with a consensus "Buy" rating based on 12 analysts. The company's expected revenue for the next quarter is $408.00K, and its EPS for the previous quarter was -$0.81 against an expectation of -$0.99.
New hires at EyePoint receive 39,700 stock options package
EyePoint (EYPT) granted non-statutory stock options for up to 39,700 shares of common stock to three new employees on June 15, 2026. These inducement awards were made under NASDAQ Listing Rule 5635(c)(4), with an exercise price of $12.08 per share and a ten-year term. The options vest over four years, with 25% after one year and the remainder in equal monthly installments over the subsequent three years, contingent on continued employment.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. (Nasdaq: EYPT) announced the grant of non-statutory stock options to three new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover an aggregate of 39,700 shares of EyePoint common stock, with an exercise price of $12.08 per share, vesting over four years. This action is part of the company's commitment to developing therapeutics for serious retinal diseases.
(EYPT) as a Liquidity Pulse for Institutional Tactics
This article analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. The analysis presents an exceptional 72.8:1 risk-reward setup, targeting a significant gain with minimal risk, and details various trading strategies across different time horizons.
EyePoint Pharmaceuticals Stock (US30233B1098): Analyst views and valuation in focus
EyePoint Pharmaceuticals (EYPT) is attracting investor attention due to a positive analyst outlook and strong 12-month stock performance, despite still trading below its 52-week high. Analysts rate the stock highly, with a consensus price target around $37, suggesting significant upside. The company's specialized Durasert E technology for severe eye diseases is a key driver of this optimistic valuation, though inherent small-cap biotech volatility remains a factor.
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance
EyePoint Pharmaceuticals is advancing its Phase III clinical trials for DURAVYU (vorolanib intravitreal insert) in patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company expects to report topline data for both pivotal trials by mid-2026. DURAVYU is designed for sustained delivery of vorolanib, offering a potential long-duration treatment option for these retinal diseases.
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
EyePoint Pharmaceuticals is nearing the release of top-line Phase 3 data for DURAVYU (EYP-1901) in wet age-related macular degeneration, with the first trial results expected in August and a second trial two months later. The company believes 2026 will be a transformative year, aiming for an every-six-month dosing label. DURAVYU combines vorolanib with EyePoint's Durasert E delivery system, and the Phase 3 trials are designed to demonstrate non-inferiority in visual acuity compared to EYLEA, continued safety, and reduced treatment burden.
(EYPT) Risk Channels and Responsive Allocation
This article from Stock Traders Daily provides an AI-generated analysis of Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), indicating weak near-term sentiment but potential long-term strength. It outlines various trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk while noting solid long-term support signals.
(EYPT) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), indicating weak near-term sentiment despite potential long-term strength. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term outlooks, highlighting support and resistance levels.
(EYPT) Movement as an Input in Quant Signal Sets
Quantitative Research Desk analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), noting weak near and mid-term sentiment, but a strong long-term outlook. The report highlights a significant 75.5:1 risk-reward setup, targeting a 23.6% gain with minimal risk, and outlines three distinct AI-generated trading strategies. These strategies – Position Trading, Momentum Breakout, and Risk Hedging – offer specific entry, target, and stop-loss levels.
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. (Nasdaq: EYPT) announced its participation in three upcoming investor conferences: Stifel 2026 Virtual Ophthalmology Forum, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. Management will provide fireside chats at each event in late May and early June 2026. The company is developing DURAVYU™, an investigational sustained delivery treatment for serious retinal diseases, with topline data for wet AMD expected in mid-2026.
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. (Nasdaq: EYPT) announced its participation in three upcoming investor conferences: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026; the Jefferies Global Healthcare Conference on June 3, 2026; and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company will conduct fireside chats at each event, with webcasts available through its investor relations website. EyePoint is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials for wet AMD and DME.
EyePoint lines up Goldman Sachs, Jefferies, Stifel fireside chats
EyePoint (Nasdaq: EYPT) announced that its management will participate in three upcoming investor conferences. The company will hold fireside chats at the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference in late May and early June 2026. Webcasts and replays of these events will be available on EyePoint's investor relations website.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, totaling 158,100 shares. These grants comply with NASDAQ Listing Rule 5635(c)(4), with an exercise price of $12.35 per share, vesting over four years. The company is focused on developing therapeutics for serious retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover an aggregate of 158,100 shares of EyePoint common stock, with an exercise price of $12.35 per share. The awards vest over four years, subject to continued employment, and are intended to attract and retain talent for the company, which focuses on developing therapeutics for serious retinal diseases.
EyePoint hands new hires 158,100 stock options at $12.35
EyePoint (Nasdaq: EYPT) granted 158,100 non-statutory stock options to eight new employees as inducement awards, under NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $12.35 per share, a ten-year term, and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly. This move reflects the company's ongoing hiring efforts amid its late-stage DURAVYU development.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to eight new employees as inducement awards, under NASDAQ Listing Rule 5635(c)(4). These options, totaling 158,100 shares, have an exercise price of $12.35 per share and vest over four years, with an initial 25% vesting on the first anniversary of the grant date. This initiative aims to attract and retain talent for the clinical-stage biopharmaceutical company focused on retinal diseases.
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review
EyePoint Pharmaceuticals received a third consecutive positive safety recommendation for its Phase 3 DURAVYU trials in wet AMD, boosting confidence ahead of mid-2026 topline data. The independent Data and Safety Monitoring Committee (DSMC) reviewed unblinded safety data from the first 200 patients and recommended continuing the trials without modification. Analysts maintain a Buy consensus with a $31.80 price target, implying a significant upside for the stock.
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review
EyePoint Pharmaceuticals announced that its two Phase 3 clinical trials for EYP-1901, an investigational treatment for wet age-related macular degeneration, have successfully cleared their first safety review by an independent Data Monitoring Committee. The committee found no safety concerns, allowing the trials to continue as planned. This brings the company closer to potentially offering a new, long-acting treatment option for patients.
EyePoint Announces Third Consecutive Positive DSMC
EyePoint, Inc. announced that its independent Data Safety Monitoring Committee (DSMC) has given a third consecutive positive recommendation for the Phase 3 wet AMD trials of DURAVYU. The trials, LUGANO and LUCIA, will continue as planned without modification, reinforcing confidence in the drug's safety profile ahead of topline data expected mid-2026. DURAVYU is being evaluated as a potential first-in-class, sustained-delivery treatment for wet age-related macular degeneration, aiming to reduce treatment burden with six-month redosing.
EyePoint’s wet AMD trial continues after safety review
EyePoint, Inc. announced that its Phase 3 trials for DURAVYU, a wet AMD treatment, will continue without modifications after an independent safety review. The company noted a favorable safety profile and reached significant dosing milestones for patients. EyePoint expects topline data from its LUGANO trial in mid-2026 and faces challenges with cash burn despite a strong balance sheet, missing Q1 2026 financial forecasts.
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials
EyePoint, Inc. (EYPT) announced that its independent Data Safety Monitoring Committee (DSMC) issued a third consecutive positive recommendation for the Phase 3 DURAVYU program for wet age-related macular degeneration (wet AMD), allowing the LUGANO and LUCIA trials to continue without modification. The company reported a favorable safety profile for DURAVYU, consistent across previous trials, with over 35% of treatment-arm patients having received a third dose by Week 56. Topline data for wet AMD is expected to begin in mid-2026, and Phase 3 trials for diabetic macular edema (DME) are also underway with data anticipated in the second half of 2027.
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed
Adage Capital Management and its affiliated reporting persons have filed an amended Schedule 13G/A, disclosing beneficial ownership of 3,300,000 shares of EyePoint, Inc. (EYPT) common stock, which represents 3.96% of the class. The filing indicates shared voting and dispositive power over these shares by Adage entities and individuals Robert Atchinson and Phillip Gross. This passive disclosure is based on EyePoint's 83,431,950 shares outstanding as of February 27, 2026.
TradingKey
This page provides an overview of EyePoint Pharmaceuticals Inc. (EYPT) on TradingKey, displaying its current stock price, market capitalization, and a loss P/E TTM ratio. It includes sections for company overview, financials, discussions, and analysis, along with a comments section. The content is primarily a stock ticker page.
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates
EyePoint Pharmaceuticals (EYPT) shares are reportedly trading at a significant discount to analyst fair value estimates, potentially offering an opportunity for investors. The biotech company specializes in ophthalmology therapeutics, leveraging its Durasert technology for sustained-release treatments for serious eye diseases. With products like YUTIQ and DEXYCU already commercialized, and pipeline assets in advanced clinical stages, EyePoint Pharmaceuticals is positioned as a key player in the growing US ophthalmology market.
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
Mizuho Securities analyst Graig Suvannavejh has reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT) with a $36.00 price target. This recommendation comes despite the company reporting a significant GAAP net loss for the last quarter. However, corporate insider sentiment on the stock is currently negative, with increased selling of shares by insiders.
Is It Too Late To Consider EyePoint (EYPT) After A 133% One-Year Surge?
EyePoint (EYPT) has seen a 133% surge over the past year. Despite recent declines, a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 84.3%, with an estimated intrinsic value of $86.91 per share compared to its current trading price of $13.66. However, its Price-to-Book ratio of 4.97x is higher than the industry average, indicating mixed valuation signals.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2026 Earnings Call Transcript
EyePoint Pharmaceuticals reported its Q1 2026 earnings, missing EPS expectations with a net loss of $85 million. The company highlighted strong progress in its Phase III trials for DURAVYU in wet AMD and DME, anticipating key data readouts mid-year and full enrollment in DME trials by Q3 2026. EyePoint emphasizes DURAVYU's potential as a best-in-class, multi-mechanism of action treatment for major retinal diseases, backed by favorable safety data and a patient-centric approach to address treatment burden.
RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating
RBC Capital updated its price target for EyePoint Pharmaceuticals (EYPT) to $37 from $39, while maintaining an Outperform Speculative-Risk rating. This adjustment comes alongside a separate report on Unity Software's fourth-quarter earnings, which showed a significant revenue increase year-over-year. The article primarily reports on analyst rating changes and mentions another company's financial results.
